Improving access to care Our businesses are finding ways to offer innovative solutions that help advance patient care with a commitment to improve access to quality care and treatment. An example of that innovation is our technology- driven patient support solution, AMP: Access for More Patients®. AMP, from CoverMyMeds, transforms how patients access, afford and adhere to their medications. Designed to automate access to therapy for patients on specialty medications for complex and chronic diseases, AMP combines the fully automated technology platform and established provider network of CoverMyMeds with our deep specialty drug expertise. Designed to support a spectrum of brands and therapies, we help customers who are looking to enhance patient adherence or broaden patient engagement. The AMP real-time hub services allow biopharma innovators to connect to patients through CoverMyMeds’ established relationships with: • More than 750,000 providers • Payers representing 94% of prescription medicine volume • 50,000+ pharmacies Innovative specialty therapies designed to treat complex and chronic diseases have led to remarkable outcomes for patients. However, with an average annual retail cost of $78,781 per year, according to the American Association of Retired Persons, for a single specialty drug, a more intricate prescribing process is typical, creating delays for patients in starting their medication. As previously published in CoverMyMeds 2020 Medication Access Report , while the high cost of specialty medications can feel like a staggering barrier, simply accessing therapy can prove even more difficult. Kathy R., a patient living with multiple sclerosis (MS), said the stress of juggling multiple provider visits and test results to manage her MS can trigger cognitive fog or “cog fog,” a momentary loss in mental clarity. “I have had full-on ‘cog fog’ flares after having to deal with this stuff,” Kathy said. “It’s too much to ask a patient to have to do, and it has affected my health. Through AMP, providers enroll patients into biopharma-sponsored access and support programs at the point of prescribing, helping millions of patients access their specialty medications in less than half the time of conventional methods such as traditional hub programs. The power behind AMP is the technology platform and the network of providers, payers, pharmacies and more than 650 life sciences brands. MCKESSON CANADA’S PPE TASKFORCE McKesson Canada’s personal protective equipment, or PPE, taskforce mobilized to leverage our global relationships and create a stream of necessary products into the Canadian market, including more than: • 1 million masks to our customers’ frontline staff • 2 million masks and 2 million gloves to government agencies • 200,000 units of shields, goggles, and hand sanitizer A healthcare gap was promptly bridged by McKesson Canada’s affiliated infusion business, INVIVA, by fast-tracking the establishment of an INVIVA infusion clinic in Halifax, Nova Scotia, in response to concerns from physicians about their patients’ risk of contracting COVID-19 while travelling to hospitals for critical infusion care. In the new INVIVA center, patients now receive treatment in a specialized clinic, closer to home. Introduction Stories Employees Access Equity Climate Operations >Table of Contents | 29 FY21 Impact Report